ANX-514: Development discontinued

Mast Therapeutics (formerly Adventrx Pharmaceuticals Inc.) discontinued development of ANX-514 last year to focus on MST-188. In October 2011, Adventrx said FDA agreed on the design of the open-label pivotal (Study 514-02) trial comparing ANX-514 without corticosteroid premedication vs. Taxotere docetaxel with corticosteroid premedication in about 400 patients who failed previous platinum-based therapy. In 2009, ANX-514 missed the primary endpoint of pharmacokinetic bioequivalence to Taxotere in a pivotal Phase I trial (see BioCentury, May 18, 2009). Shin Poong has South Korean rights to ANX-514 from Adventrx. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere. ...